:::

關於癌醫

:::

徐志宏副院長

徐志宏副院長

徐志宏Chih-Hung Hsu

一般腫瘤 肝/膽/食道/胃腸癌

  • 服務機構 服務部門／系所 職稱 服務起迄
    臺灣大學醫學院 腫瘤醫學研究所 教授 2016/01-迄今
    臺大癌醫中心醫院 院長室 副院長 2025/08-迄今
    臺大癌醫中心醫院 腫瘤內科部 專任主治醫師 2025/08-迄今
    臺大癌醫中心醫院 企劃暨管理室 主任 2025/08-迄今
    臺大醫院 腫瘤醫學部 副主任 2020/08-迄今
    臺大醫院 腫瘤醫學部 主治醫師 1998/01-迄今
    臺大醫院 癌症防治中心 副主任 2020/08-迄今
  • 服務機構 服務部門／系所 職稱 服務起迄
    臺大癌醫中心醫院 腫瘤內科部 兼任主治醫師 2020/08-2025/07
    臺大癌醫中心醫院 腫瘤內科部 主任 2019/03-2020/07
  • 學校名稱 主修學門系所 學位 起迄年月
    臺灣大學醫學院 臨床醫學研究所 博士 1997/08-2003/01
    臺灣大學醫學院 醫學系 醫學士 1983/08-1990/06
  • 獎助名稱 獲獎時間
    財團法人肝病防治學術基金會 宋瑞樓教授紀念特別獎 2022/08
    1. Lu LC, Hsu C, Shao YY, Chao Y, Yen CJ, Shih IL, Hung YP, Chang CJ, Shen YC, Guo JC, Liu TH, Hsu CH*, Cheng AL*: Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma. Liver Cancer 2019 Nov; 8(6):480-490. [Epub 2019 Aug 06] (* correspondence)
    2. Huang TC, Lin CC, Wu YC, CH Cheng J, Lee JM, Wang HP, Huang PM, Hsu FM, Yeh KH, Cheng AL, Tzen KY, Hsu CH*: Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. J Formos Med Assoc. 2019 Jun 1; 118(6):1024-1030. [Epub 2018 Nov 27] (* correspondence)
    3. Lu LC, Lee YH, Chang CJ, Shun CT, Fang CY, Shao YY, Liu TH, Cheng AL*, Hsu CH*: Increased expression of programmed death-ligand 1 in infiltrating immune cells in hepatocellular carcinoma tissues after sorafenib treatment. Liver Cancer 2019 Mar; 8(2):110–120. [Epub 2018 Jun 15] (* correspondence)
    4. Chang CJ, Yang YH, Chiu CJ, Lu LC, Liang CW, Hsu CH*, Cheng AL*: Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma. Int J Cancer 2018 May 1;142(9):1878-1889. [Epub 2017 Dec 20] (* correspondence)
    5. Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH*, Cheng AL: Inhibition of the Wnt /β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma . Cancer Lett 2016 Jul 16;381(1): 58-66. [Epub 2016 Jul 15] (* correspondence)
    6. Guo JC, Huang TC, Lin CC, Hsieh MS, Chang CH, Huang PM, Lee JM, Hsu FM, Cheng JC, Wang HP, Yeh KH, Cheng AL, Hsu CH*: Postchemoradiotherapy pathologic stage classified by the American Joint Committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma. J Thoracic Oncol 2015 Oct; 10(10): 1481-9. (* correspondence)
    7. Lin TH, Shao YY, Chan SY, Huang CY, Hsu CH*, Cheng AL: High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib. Clin Cancer Res 2015 Aug 15; 21(16): 3678-84. [Epub 2015 May 14] (* correspondence)
    8. Hsu CH*, Shen YC, Shao YY, Hsu C, Cheng AL: Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. Journal of Hepatocellular Carcinoma 2014 June; 1: 85-99.
    9. Shao YY, Wu CH, Lu LC, Chan SY, Ma YY, Yen FC, Hsu CH*, Cheng AL*: Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. J Hepatol 2014 Feb; 60(2): 313-8. [Epub 2013 Sep 11] (* correspondence)
    10. Shao YY, Huang CC, Lin SD, Hsu CH*, Cheng AL*: Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving anti-angiogenic therapy. Clin Cancer Res 2012 Jul 15; 18(14): 3992-7. [Epub 2012 May 23] (* correspondence)
    11. Shao YY, Lin ZZ, Hsu C, Lee KD, Hsiao CH, Lu YS, Huang CC, Shen YC, Hsu CH*, Cheng AL: Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology 2012; 82(1): 59-66. [Epub 2012 Feb 4] (*correspondence)
    12. Hsu CH*, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL: Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 2010 Jul; 53(1): 126-131. [Epub 2010 Mar 30]
    13. Hsu CH*, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL: Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Brit J Cancer 2010 Mar 16; 102(6): 981-6. [Epub 2010 Feb 16]
    14. Hsu CH* and Cheng AL: Clinical studies with curcumin. Adv Exp Med Biol 2007; 595: 471-80.
    15. Lin CC#, Hsu CH*#, Cheng JC, Wang HP, Lee JM, Yeh KH, Yang CH, Lin JT, Cheng AL, Lee YC: Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007 Jan; 18(1): 93-98. [Epub 2006 Oct 6] (#equal contribution)
    16. Hsu CH*, Liou JY, Dutschman GE, Cheng YC: Phosphorylation of cytidine-, deoxycytidine-, and their analog- monophosphates by human UMP/CMP kinase is differentially regulated by ATP and magnesium. Mol Pharmacol 2005 Mar; 67(3): 806-14.
    17. Hsu CH*, Chen CL, Hong RL, Chen KL, Lin JF, Chen AL: Prognostic value of multidrug resistance 1 (MDR1), glutathione-S-transferase π (GST π), and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy. Oncology 2002; 62 (4): 305-12.
    18. Hsu CH*, Yeh KH, Lui Louis T, Lee YC, Bu CF, Wang HP, Lin JT, Cheng AL: Concurrent chemoradiotherapy for locally advanced esophageal cancer—a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil. Anticancer Res 1999 Sep-Oct; 19 (5C): 4463-4468.
    19. Hsu CH*, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, Chen YC, Cheng AL: Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers  an effective and low-toxic regimen for patients with poor general condition. Oncology 1997 Jul-Aug; 54 (4): 275-280.



最後更新：

:::

將另開新視窗，連結至臺大癌醫以外的網站！

回到最上面